AlloVir Inc has a consensus price target of $12.64 based on the ratings of 8 analysts. The high is $27 issued by Morgan Stanley on September 9, 2022. The low is $1 issued by B of A Securities on December 26, 2023. The 3 most-recent analyst ratings were released by B of A Securities, Leerink Partners, and Piper Sandler on December 26, 2023, December 22, 2023, and December 22, 2023, respectively. With an average price target of $1.17 between B of A Securities, Leerink Partners, and Piper Sandler, there's an implied 52.41% upside for AlloVir Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for AlloVir (NASDAQ:ALVR) was reported by B of A Securities on December 26, 2023. The analyst firm set a price target for $1.00 expecting ALVR to rise to within 12 months (a possible 26.86% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for AlloVir (NASDAQ:ALVR) was provided by B of A Securities, and AlloVir downgraded their underperform rating.
There is no last upgrade for AlloVir
The last downgrade for AlloVir Inc happened on December 26, 2023 when B of A Securities changed their price target from $17 to $1 for AlloVir Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AlloVir, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AlloVir was filed on December 26, 2023 so you should expect the next rating to be made available sometime around December 26, 2024.
While ratings are subjective and will change, the latest AlloVir (ALVR) rating was a downgraded with a price target of $17.00 to $1.00. The current price AlloVir (ALVR) is trading at is $0.79, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.